Cargando…

P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY

Detalles Bibliográficos
Autores principales:	Zhi-Ming, LI, Liu, Chuanxu, Sun, Peng, Tian, Shu, Ding, Hao, Tao, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430915/ http://dx.doi.org/10.1097/01.HS9.0000971372.50510.47

Ejemplares similares

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma
por: Hu, Shaoxuan, et al.
Publicado: (2022)

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Lan, Chunyan, et al.
Publicado: (2020)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China
por: Liang, Rong, et al.
Publicado: (2016)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
por: Liang, J-H, et al.
Publicado: (2017)

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
por: Shen, Jie, et al.
Publicado: (2023)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study
por: Chen, Dongbo, et al.
Publicado: (2023)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Publicado: (2020)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
por: wang, T., et al.
Publicado: (2022)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45vk11j38nhei2bbq86li6atav